PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Hepatology"
DOI: 10.1002/hep.30307
Abstract: Class I phosphoinositide 3‐kinase (PI3K) signaling is a major pathway in human cancer development and progression. Among the four PI3K isoforms, PI3Kα and PI3Kβ are ubiquitously expressed, whereas PI3Kγ and PI3Kδ are found primarily in… read more here.
Keywords: hepatocellular carcinoma; pi3k; hcc; advanced hcc ... See more keywords
Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?
Sign Up to like & getrecommendations! Published in 2019 at "Investigational New Drugs"
DOI: 10.1007/s10637-019-00760-0
Abstract: SummaryThe second line treatment of hepatocellular carcinoma (HCC) has recently become an exciting area of interest since new emerging options have demonstrated survival benefits versus placebo. Unfortunately, predictive biomarkers are unavailable for these treatments. Ramucirumab,… read more here.
Keywords: advanced hcc; therapy advanced; therapy; line therapy ... See more keywords
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
Sign Up to like & getrecommendations! Published in 2020 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2020.103167
Abstract: Advanced hepatocellular carcinoma (HCC) is the most frequent liver cancer. Immunotherapy has been explored in this disease in order to improve survival outcomes. Nowadays, scientific research is focusing especially on immune checkpoint inhibitors, in particular… read more here.
Keywords: hepatocellular carcinoma; immunotherapy; immunotherapy advanced; advanced hepatocellular ... See more keywords
Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of clinical and experimental hepatology"
DOI: 10.1016/j.jceh.2019.07.012
Abstract: Hepatocellular carcinoma (HCC) incidence and mortality have shown an unfavorable upward trend over the last two decades, especially in developed countries. More than one-sixth of the patients have advanced HCC at presentation. Systemic therapy remains… read more here.
Keywords: hepatocellular carcinoma; therapy; advanced hcc; systemic therapy ... See more keywords
Camrelizumab: an investigational agent for hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Expert opinion on investigational drugs"
DOI: 10.1080/13543784.2022.2022121
Abstract: INTRODUCTION : Although many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits were limited, particularly for advanced HCC. However, recent treatments with PD-1/PD-L1 inhibitor monotherapy and its combination with other therapies,… read more here.
Keywords: hepatocellular carcinoma; camrelizumab investigational; camrelizumab; investigational agent ... See more keywords
Chemotherapy for hepatocellular carcinoma: current status and future perspectives
Sign Up to like & getrecommendations! Published in 2018 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyx180
Abstract: Chemotherapy is one of the most important treatment modalities for advanced hepatocellular carcinoma (HCC). On the basis of the results of two pivotal Phase III placebo-controlled studies, sorafenib is currently acknowledged worldwide as the standard… read more here.
Keywords: hepatocellular carcinoma; chemotherapy; treatment; sorafenib ... See more keywords
Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC
Sign Up to like & getrecommendations! Published in 2019 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-019-0766-y
Abstract: BackgroundCurrently, there are no imaging predictors of immunotherapy outcome in hepatocellular carcinoma (HCC). The study aim was to determine if stiffness changes measured by magnetic resonance elastography (MRE) can be a predictor of immunotherapy response… read more here.
Keywords: mre; stiffness; hcc stiffness; immunotherapy response ... See more keywords
Immunotherapy response evaluation with MR elastography (MRE) in advanced HCC.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.4_suppl.230
Abstract: 230 Background: To determine changes in MRE HCC stiffness as predictor of immunotherapy response in patients with advanced HCC. Methods: This was a prospective, Institutional Review Board approved study of 15 patients with biopsy proven… read more here.
Keywords: hcc stiffness; hcc; advanced hcc; stiffness ... See more keywords
Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of gastrointestinal oncology"
DOI: 10.21037/jgo-22-395
Abstract: Background Targeted drug therapy and transcatheter arterial chemoembolization (TACE) is the most effective control method for middle and late-stage hepatocellular carcinoma (HCC). Regorafenib as the second-line treatment of patients with advanced HCC, combined with TACE… read more here.
Keywords: advanced hcc; regorafenib; line; treatment ... See more keywords
Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.685126
Abstract: Advanced hepatocellular carcinoma (HCC) is a highly lethal disease, mainly due to the late stage at diagnosis and its rapid progression. Although patients with advanced HCC can choose targeted therapy or chemotherapy, overall, the treatment… read more here.
Keywords: neoantigen reactive; reactive cells; hcc patient; advanced hcc ... See more keywords
Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.896752
Abstract: Hepatocellular carcinoma (HCC) is usually diagnosed in an advanced stage and has become the second deadliest type of cancer worldwide. The systemic treatment of advanced HCC has been a challenge, and for decades was limited… read more here.
Keywords: advanced hcc; hepatocellular carcinoma; checkpoint inhibitors; immune checkpoint ... See more keywords